WO2024128298A1 - Agent pour améliorer l'endurance et/ou réduire la fatigue physique - Google Patents
Agent pour améliorer l'endurance et/ou réduire la fatigue physique Download PDFInfo
- Publication number
- WO2024128298A1 WO2024128298A1 PCT/JP2023/044944 JP2023044944W WO2024128298A1 WO 2024128298 A1 WO2024128298 A1 WO 2024128298A1 JP 2023044944 W JP2023044944 W JP 2023044944W WO 2024128298 A1 WO2024128298 A1 WO 2024128298A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- improving
- sialyllactose
- salt
- endurance
- agent
- Prior art date
Links
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims abstract description 82
- 150000003839 salts Chemical class 0.000 claims abstract description 77
- 239000012190 activator Substances 0.000 claims abstract description 52
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 35
- 108010001483 Glycogen Synthase Proteins 0.000 claims abstract description 31
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 28
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims abstract description 28
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 108060006633 protein kinase Proteins 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 14
- 230000004153 glucose metabolism Effects 0.000 claims abstract description 13
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 12
- 208000001076 sarcopenia Diseases 0.000 claims abstract description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 12
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 34
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 32
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 3
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 3
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical group O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 3
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 description 28
- 241000244206 Nematoda Species 0.000 description 26
- 235000013305 food Nutrition 0.000 description 22
- 239000002207 metabolite Substances 0.000 description 22
- 230000009182 swimming Effects 0.000 description 22
- 229920001817 Agar Polymers 0.000 description 17
- 239000008272 agar Substances 0.000 description 17
- -1 sialic acid compound Chemical class 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 9
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000244202 Caenorhabditis Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241001167795 Escherichia coli OP50 Species 0.000 description 7
- 101150007813 NIH gene Proteins 0.000 description 7
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 7
- 230000037081 physical activity Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 6
- 229940096919 glycogen Drugs 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 101100000320 Caenorhabditis elegans aak-1 gene Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000244203 Caenorhabditis elegans Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 101150075588 gsy-1 gene Proteins 0.000 description 4
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical class OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 235000008729 phenylalanine Nutrition 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000005051 trimethylchlorosilane Substances 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 2
- 101100149536 Caenorhabditis elegans skn-1 gene Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101150118144 aak-1 gene Proteins 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000019439 energy homeostasis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000002705 metabolomic analysis Methods 0.000 description 2
- 230000001431 metabolomic effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000008437 mitochondrial biogenesis Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100321927 Caenorhabditis elegans aak-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004265 EU approved glazing agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical class OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 244000188472 Ilex paraguariensis Species 0.000 description 1
- 235000003368 Ilex paraguariensis Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 101100083855 Rattus norvegicus Pou2f3 gene Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101150077059 TPS1 gene Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 101150054245 aak-2 gene Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical class OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229940032713 merrem Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000037931 necrotizing enteritis Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940093956 potassium carbonate Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 101150040893 skn-1 gene Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an agent for at least one of improving endurance and reducing physical fatigue, use of sialyllactose or a salt thereof for producing the agent, sialyllactose or a salt thereof for use as the agent, a method for at least one of a method for improving endurance and a method for reducing physical fatigue, an adenosine monophosphate protein kinase activator, a composition for preventing sarcopenia, improving lipid metabolism, improving insulin resistance, and improving glucose metabolism, a glycogen synthase activator, and a composition for improving endurance.
- Endurance is the ability to maintain a certain level of physical activity. Endurance is not limited to competitive sports such as marathons, but is essential for sustaining all physical activity, including work, housework, walking, and other daily activities. A decrease in activity capacity caused by overload of physical activity is called physical fatigue. By improving endurance, you can create a body that does not tire easily and can maintain a healthy daily life, which can be expected to speed up recovery from physical fatigue.
- Sialyllactose (hereinafter also referred to as "SL") is a sialic acid compound in which lactose and N-acetylneuraminic acid are bonded, and is a type of oligosaccharide found in breast milk, cow's milk, and dairy products.
- the SLs found in human breast milk are known to be 3'-sialyllactose (hereinafter also referred to as "3'-SL”), in which N-acetylneuraminic acid is bonded to the galactose residue of lactose via an ⁇ 2-3 bond, and 6'-sialyllactose (hereinafter also referred to as "6'-SL”), in which N-acetylneuraminic acid is bonded via an ⁇ 2-6 bond.
- 3'-SL 3'-sialyllactose
- 6'-SL 6'-sialyllactose
- Non-Patent Document 1 discloses that SL acts as a prebiotic and contributes to the formation and development of the intestinal flora of infants and young children, and also exhibits a preventive effect against pathogenic bacteria infection, including pathogenic Escherichia coli, in the maturation of intestinal tissue and in the intestine.
- pathogenic bacteria infection including pathogenic Escherichia coli
- immunostimulatory and anti-inflammatory actions specifically effects against irritable colitis and necrotizing enteritis, are also disclosed.
- Patent Literature 1 discloses that SL acts on the central nervous system, including improving memory function, by regulating gangliosides in the brain, while Patent Literature 2 reports that the action of SL on the central nervous system improves fatigue.
- the present invention therefore aims to provide an agent for improving endurance and/or reducing physical fatigue, which contains sialyllactose or a salt thereof as an active ingredient.
- an agent containing sialyllactose or a salt thereof as an active ingredient exhibits endurance-improving effects and physical fatigue-reducing effects, and further discovered that these effects are due to the adenosine monophosphate protein kinase activating effect or glycogen synthase activating effect of sialyllactose or a salt thereof, thus completing the present invention.
- the present invention relates to the following.
- An agent for improving endurance and/or reducing physical fatigue comprising sialyllactose or a salt thereof as an active ingredient.
- Sialyllactose or a salt thereof for use as an agent for improving endurance and/or reducing physical fatigue.
- a glycogen synthase activator comprising sialyllactose or a salt thereof as an active ingredient.
- a composition for improving endurance comprising the activator according to [8] as an active ingredient.
- the present invention also relates to the following: Use of sialyllactose or a salt thereof for producing an adenosine monophosphate protein kinase activator. Sialyllactose or a salt thereof for use as an adenosine monophosphate protein kinase activator. A method for activating adenosine monophosphate protein kinase, comprising administering sialyllactose or a salt thereof.
- an adenosine monophosphate protein kinase activator containing sialyllactose or a salt thereof as an active ingredient to manufacture a composition for one or more of the following: prevention of sarcopenia, improvement of lipid metabolism, improvement of insulin resistance, and improvement of glucose metabolism.
- One or more methods for preventing sarcopenia, improving lipid metabolism, improving insulin resistance, and improving glucose metabolism comprising administering an adenosine monophosphate protein kinase activator containing sialyllactose or a salt thereof as an active ingredient.
- sialyllactose or a salt thereof for producing a glycogen synthase activator.
- a method for activating glycogen synthase comprising administering sialyllactose or a salt thereof.
- glycogen synthase activator containing sialyllactose or a salt thereof as an active ingredient for producing a composition for improving endurance A glycogen synthase activator containing sialyllactose or a salt thereof as an active ingredient for use as a composition for improving endurance.
- a method for improving endurance comprising administering a glycogen synthase activator containing sialyllactose or a salt thereof as an active ingredient.
- the agent of the present invention contains sialyllactose or a salt thereof as an active ingredient, which can improve endurance and/or reduce physical fatigue.
- the agent of the present invention contains sialyllactose or a salt thereof as an active ingredient, which can activate adenosine monophosphate protein kinase and/or glycogen synthase.
- FIG. 1 is a graph showing the distance traveled immediately after swimming exercise of nematodes reared in the presence of 3'-SL, 6'-SL, sialic acid, or lactose.
- FIG. 2 shows a heat map and a dendrogram of metabolites in nematodes after they were reared in the presence of 3'-SL or 6'-SL and subjected to swimming exercise.
- FIG. 3 is a graph showing the oxygen consumption rate in mitochondria of nematodes reared in the presence of 3'-SL or 6'-SL.
- FIG. 4 is a graph showing the distance traveled by nematodes lacking a specific gene that were reared in the presence of 3'-SL or 6'-SL and subjected to swimming exercise.
- FIG. 5 is a graph showing the distance traveled by nematodes lacking a specific gene that were reared in the presence of 3'-SL or 6'-SL and subjected to swimming exercise.
- the present invention will be described in detail below, but these are merely examples of preferred embodiments and the present invention is not limited to these contents.
- the numerical range “to” includes the numerical values before and after it. For example, "0% by mass to 100% by mass” means a range from 0% by mass or more to 100% by mass or less.
- the agent for improving endurance and/or reducing physical fatigue contains sialyllactose or a salt thereof as an active ingredient.
- the agent for improving endurance and/or reducing physical fatigue contains SL or a salt thereof as an active ingredient, and can contribute to improving endurance or reducing physical fatigue. Furthermore, the endurance-improving effect and physical fatigue-reducing effect of SL are due to the activation of adenosine monophosphate protein kinase (hereinafter also referred to as "AMPK") and the activation of glycogen synthesis.
- AMPK adenosine monophosphate protein kinase
- AMPK is encoded by, for example, the aak-1 gene of humans or nematodes, and is an important regulatory protein involved in maintaining intracellular energy homeostasis. AMPK promotes energy metabolism by sensing the intracellular energy state and regulating lipid metabolism and glucose metabolism. AMPK is distributed in many organs and tissues, such as the liver and heart, and is a master regulator that mediates beneficial cellular adaptations in many important tissues and organs. Such adaptations are also beneficial in exercise and various physical activities. It is known that AMPK is also activated by exercise (Annu Rev Physiol, 2022 Feb 10, 84, 209-227.), and that exercise-induced activation of AMPK improves endurance (Cell, 2008 Aug 8, 134(3), 405-415.).
- AMPK is known to be activated by exercise, fat cell-derived hormones such as leptin (Nature, 2002, volume 415, pages 339-343.) and adiponectin (Cell Metab, 2007 Jul, 6(1), 55-68.), and some diabetes treatment drugs such as metformin (J Clin Invest, 2001 Oct 15, 108(8), 1167-1174.).
- AMPK is thought to contribute to the prevention or improvement of lifestyle-related diseases such as obesity and diabetes through the improvement of lipid metabolism, glucose metabolism, and insulin resistance (J Clin Invest, 2013 Jul, 123(7), 2764-2772.).
- the SL or a salt thereof of the present invention can be used as an AMPK activator, and further can be used as a composition containing this AMPK activator as an active ingredient for one or more of the following purposes: preventing sarcopenia, improving lipid metabolism, improving insulin resistance, and improving glucose metabolism.
- Glycogen is mainly synthesized in the liver and skeletal muscles, and glycogen in skeletal muscles is used as an energy source for muscle contraction. It has been disclosed that mice lacking glycogen synthase specifically in muscle have reduced endurance (Molecular metabolism, 2016, Volume 5, Issue 3, 221-232.), and glycogen is known to affect endurance. Glycogen synthase is encoded by the gsy-1 gene of humans or nematodes, for example. Therefore, the SL or a salt thereof of the present invention can be used as a glycogen synthase activator containing them as an active ingredient, and further can be used as a composition for improving endurance containing this glycogen synthase activator as an active ingredient.
- the SL used in the present invention may be 3'-SL or 6'-SL.
- the SL used in the present invention may be obtained by any production method, such as fermentation, enzymatic methods, extraction from natural products, or chemical synthesis.
- salts of SL include acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts.
- acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate, and organic acid salts such as acetate, maleate, fumarate, citrate, malate, lactate, ⁇ -ketoglutarate, gluconate, and caprylate.
- metal salts include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as magnesium salts and calcium salts, aluminum salts, zinc salts, etc.
- ammonium salts include salts of ammonium and tetramethylammonium, etc.
- organic amine addition salts include salts of morpholine and piperidine, etc.
- amino acid addition salts include salts of glycine, phenylalanine, lysine, aspartic acid, and glutamic acid.
- SL salts sodium salts are preferably used, but other salts or a suitable combination of two or more salts may also be used.
- an adenosine monophosphate protein kinase activator or a glycogen synthase activator according to an embodiment of the present invention, SL or a salt thereof can be administered as is, but it is usually preferable to provide it as a preparation of various kinds.
- the agent for improving endurance and/or reducing physical fatigue, adenosine monophosphate protein kinase activator or glycogen synthase activator according to the embodiment of the present invention can be a formulation in any form.
- the formulation can be prepared by mixing the active ingredient with one or more pharmacologically acceptable carriers and by any method well known in the technical field of pharmaceuticals.
- the formulation may further contain any other active ingredient for treatment.
- additives such as excipients, binders, disintegrants, lubricants, dispersants, suspending agents, emulsifiers, diluents, buffers, antioxidants, and bacteria inhibitors can be used.
- Dosage forms may include oral preparations such as tablets, powders, granules, pills, suspensions, emulsions, infusions/decoctions, capsules, syrups, liquids, elixirs, extracts, tinctures, and liquid extracts, as well as parenteral preparations such as injections, drips, creams, and suppositories, with oral preparations being preferred.
- oral preparations such as tablets, powders, granules, pills, suspensions, emulsions, infusions/decoctions, capsules, syrups, liquids, elixirs, extracts, tinctures, and liquid extracts, as well as parenteral preparations such as injections, drips, creams, and suppositories, with oral preparations being preferred.
- the formulation can be prepared by adding sugars such as lactose, glucose, sucrose, mannitol, and sorbitol; starches from potato, wheat, corn, and the like; inorganic substances such as calcium carbonate, calcium sulfate, sodium bicarbonate, and sodium chloride; excipients such as crystalline cellulose, plant powders such as licorice powder and gentian powder; disintegrants such as starch, agar, gelatin powder, crystalline cellulose, carmellose sodium, carmellose calcium, calcium carbonate, sodium bicarbonate, and sodium alginate; lubricants such as magnesium stearate, talc, hydrogenated vegetable oil, macrogol, and silicone oil; binders such as polyvinyl alcohol, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, carmellose, gelatin, and starch paste; surfactants such as fatty acid esters; and
- the dosage form suitable for oral administration is a liquid preparation such as a syrup
- it can be formulated by adding water, sugars such as sucrose, sorbitol, and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil, and soybean oil, preservatives such as p-hydroxybenzoic acid esters, parahydroxybenzoic acid derivatives such as methyl parahydroxybenzoate, preservatives such as sodium benzoate, and flavors such as strawberry flavor and peppermint.
- sugars such as sucrose, sorbitol, and fructose
- glycols such as polyethylene glycol and propylene glycol
- oils such as sesame oil, olive oil, and soybean oil
- preservatives such as p-hydroxybenzoic acid esters, parahydroxybenzoic acid derivatives such as methyl parahydroxybenzoate, preservatives such as sodium benzoate, and flavors such as strawberry flavor and peppermint.
- the dosage form suitable for parenteral administration is an injection
- it is preferably composed of a sterile aqueous agent containing SL or a salt thereof that is isotonic with the blood of the recipient.
- a solution for injection can be prepared using a carrier consisting of a salt solution, a glucose solution, or a mixture of a salt solution and a glucose solution.
- additives generally used in food and beverages may be added to a preparation suitable for oral administration.
- additives include sweeteners, colorants, preservatives, thickening stabilizers, antioxidants, colorants, bleaching agents, fungicides, gum bases, bittering agents, enzymes, glazing agents, acidulants, seasonings, emulsifiers, strengthening agents, manufacturing agents, fragrances, and spice extracts.
- the dosage form of the preparation is preferably the most effective one for improving endurance and/or reducing physical fatigue, and may be oral or parenteral, such as intravenous, intraperitoneal or subcutaneous, with oral administration being preferred.
- the concentration of SL or a salt thereof in the agent for improving endurance and/or reducing physical fatigue is appropriately selected depending on the type of preparation and the effect expected from administration of the preparation, etc., but for example, in the case of an oral preparation, the concentration of SL or a salt thereof is preferably 0.1 to 100% by mass, more preferably 0.2 to 100% by mass, even more preferably 1 to 100% by mass, particularly preferably 50 to 100% by mass, and most preferably 80 to 100% by mass.
- the agent for improving endurance and/or reducing physical fatigue may further contain a component having an endurance exercise effect, so long as the effect of the present invention is not impaired.
- a component having an endurance exercise effect include B vitamins, caffeine, green tea extract such as catechin, L-carnitine, capsaicin, taurine, branched amino acids (valine, leucine, isoleucine), citrulline, arginine, ⁇ -alanine, astaxanthin, carnosine, carnitine, ⁇ -lipoic acid, coenzyme Q10, etc.
- the agent for improving endurance and/or reducing physical fatigue may be taken together with a protein or a supplement having a fat burning effect.
- the protein may be a commercially available product obtained by extracting and purifying protein contained in animals or plants.
- Target subjects for administration in the present invention include, but are not limited to, humans or animals in need of reducing fatigue caused by physical activity in daily life, improving endurance and reducing fatigue in work involving muscular exertion, improving endurance during exercise in the narrow sense, and promoting recovery from fatigue during or after exercise in the narrow sense.
- the agent for improving endurance and/or reducing physical fatigue can be used in a form suitable for human or animal food, medicine, or quasi-drug.
- an adenosine monophosphate protein kinase activator or a glycogen synthase activator can be used in foods, functional foods, foods for the sick, and foods for specified health uses that are labeled as improving endurance and/or reducing physical fatigue.
- General foods and beverages include, for example, various beverages, various foods, processed foods, liquid foods (such as soups), seasonings, nutritional drinks, and confectioneries.
- processed foods refers to natural ingredients (such as animals and plants) that have been processed and/or cooked.
- processed foods include processed meat products, processed vegetable products, processed fruit products, frozen foods, retort foods, canned foods, bottled foods, and instant foods.
- the foods of the present invention may also be provided in a form sealed in a bag or container.
- the bags and containers used in the present invention may be any bags and containers normally used for foods.
- the shape of the food can be in any food shape that is normally distributed, such as a solid (e.g., powder or granules), liquid, liquid food, jelly, tablet, granule, capsule, paste, or suspension.
- Food can be produced by a method commonly used by those skilled in the art, and carbohydrates, proteins, lipids, dietary fiber, vitamins, biologically essential trace metals (e.g., manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), flavorings, and other ingredients may be added, so long as they do not interfere with at least one of the effects of SL or its salts of improving endurance and reducing physical fatigue.
- the amount of SL or a salt thereof in the above-mentioned composition varies depending on the form of use, but in the form of food, it is preferably 5 to 70% by mass, more preferably 10 to 60% by mass, and even more preferably 20 to 60% by mass. In the case of beverages, it is preferably 0.05 to 10% by mass, more preferably 0.1 to 5% by mass, and even more preferably 0.5 to 3% by mass. In the case of food tablets such as tablets and/or capsules, it is preferably 10 to 95% by mass, more preferably 20 to 90% by mass, and even more preferably 50 to 85% by mass.
- the amount of SL or a salt thereof is preferably 0.01 to 100% by mass, more preferably 0.5 to 80% by mass, and even more preferably 1 to 70% by mass.
- the present invention also encompasses the following: - Use of sialyllactose or a salt thereof for producing an agent for improving endurance and/or reducing physical fatigue. - Sialyllactose or a salt thereof for use as an agent for improving endurance and/or reducing physical fatigue. - A method which is at least one of a method for improving endurance and a method for reducing physical fatigue, comprising administering sialyllactose or a salt thereof. Use of sialyllactose or a salt thereof for producing an adenosine monophosphate protein kinase activator. Sialyllactose or a salt thereof for use as an adenosine monophosphate protein kinase activator.
- a method for activating adenosine monophosphate protein kinase comprising administering sialyllactose or a salt thereof.
- sialyllactose or a salt thereof as an active ingredient to manufacture a composition for one or more of the following: prevention of sarcopenia, improvement of lipid metabolism, improvement of insulin resistance, and improvement of glucose metabolism.
- An adenosine monophosphate protein kinase activator containing sialyllactose or a salt thereof as an active ingredient for use as a composition for one or more of preventing sarcopenia, improving lipid metabolism, improving insulin resistance, and improving glucose metabolism.
- One or more methods for preventing sarcopenia, improving lipid metabolism, improving insulin resistance, and improving glucose metabolism which comprise administering an adenosine monophosphate protein kinase activator containing sialyllactose or a salt thereof as an active ingredient.
- sialyllactose or a salt thereof for producing a glycogen synthase activator.
- a method for activating glycogen synthase comprising administering sialyllactose or a salt thereof.
- a glycogen synthase activator containing sialyllactose or a salt thereof as an active ingredient for producing a composition for improving endurance A glycogen synthase activator containing sialyllactose or a salt thereof as an active ingredient for use as a composition for improving endurance.
- a method for improving endurance comprising administering a glycogen synthase activator containing sialyllactose or a salt thereof as an active ingredient.
- the dosage and frequency of administration of the agent for improving endurance and/or reducing physical fatigue, adenosine monophosphate protein kinase activator, glycogen synthase activator, etc. will vary depending on the administration form, the age and weight of the recipient, and the nature or severity of the symptoms to be improved, but will generally be administered once or several times a day so that the daily dose of SL or a salt thereof for an adult is preferably 50 mg to 30 g, more preferably 100 mg to 10 g, and particularly preferably 200 mg to 3 g.
- the dosage and frequency of administration of the agent for improving endurance and/or reducing physical fatigue is not particularly limited, and may be administered, for example, before or after physical activity in daily life, work involving muscular exertion, or exercise in the narrow sense that may cause fatigue, but it is preferable to administer it before physical activity in daily life, work involving muscular exertion, or exercise in the narrow sense.
- Example 1 Based on the literature (Laranjeiro, Ricardo, Girish Harinath, Daniel Burke, Bart P. Braeckman, and Monica Driscoll. 2017. “Single Swim Sessions in C. Elegans Induce Key Features of Mammalian Exercise.” BMC Biology15 (1).), the effect of administering SL on endurance was evaluated using the nematode Caenorhabditis elegans N2 strain (obtained from the Caenorhabditis Genetics Center).
- nematode eggs were synchronized by stirring for 45 to 60 seconds using a 2% hypochlorous acid solution, and then cultured overnight in M9 buffer (3 g/L KH2PO4 , 6 g/L Na2HPO4 , 5 g/L NaCl, 1 mM MgSO4 ) to obtain larvae immediately after hatching (hereinafter referred to as L1 larvae).
- M9 buffer 3 g/L KH2PO4 , 6 g/L Na2HPO4 , 5 g/L NaCl, 1 mM MgSO4
- the obtained L1 larvae were synchronized, and then about 200 L1 larvae per plate were reared in an incubator at 20°C for 11 days on NGM agar plates (3 g/L NaCl, 17 g/L agar, 2.5 g/L peptone, 1 mM CaCl2 , 5 mg/L cholesterol (dissolved in ethanol), 1 mM MgSO4 , 25 mM KPO4 buffer (pH 6)) coated with the following evaluation samples and E. coli OP strain (obtained from Caenorhabditis Genetics Center).
- the reared nematodes (hereinafter referred to as "aged animals") were subjected to a swimming exercise stress test described below.
- SIA sialic acid
- LAC lactose
- the aged animals were suspended in M9-Tween buffer (3 g/L KH 2 PO 4 , 6 g/L Na 2 HPO 4 , 5 g/L NaCl, 1 mM MgSO 4 ) for each plate, collected in a 15 mL tube, centrifuged (2,500 rpm, 1 minute), and the supernatant was removed to collect the nematodes.
- 2 ml of M9-Tween buffer was added to the collected nematodes, and they were subjected to swimming exercise in the buffer for 120 minutes.
- the nematodes reared on the control plate were divided into a group subjected to swimming exercise (control group) and a control group not subjected to swimming exercise.
- the control group not subjected to swimming exercise was reared for another 120 minutes on an NGM agar plate coated with E. coli OP50 strain, instead of being suspended in M9-Tween buffer and subjected to swimming exercise.
- Example 2 In order to analyze the mechanism of the endurance-improving effect of 3'-SL or 6'-SL found in Example 1, metabolite profiles were analyzed when 3'-SL or 6'-SL was administered to nematodes and they were subjected to an exercise load.
- Example 2 L1 larvae obtained in the same manner as in Example 1 were synchronized and then reared on NGM agar plates coated with E. coli OP strain in an incubator at 16° C. for 96 hours.
- the NGM agar plates were the same as in Example 1.
- the number of L1 larvae reared was about 200/plate, and the amount of E. coli OP50 strain applied was about 10 cfu/plate.
- the nematodes thus reared were collected and further reared on NGM agar plates supplemented with 3'-SL or 6'-SL and E. coli OP strain in the same manner as in Example 1.
- the concentration of 3'-SL or 6'-SL added was 2 mg/ml. Purified water was used as a control.
- the amount of E. coli OP50 strain applied was approximately 10 7 cfu/plate.
- Example 2 the nematodes were suspended in M9-Tween buffer, collected, and subjected to swimming exercise.
- a control group (Control group) was set up in which the nematodes were raised on NGM agar plates coated with E. coli OP strain, and a group (Crawling group) was set up in which the nematodes were allowed to move freely on NGM agar plates not coated with E. coli OP strain.
- the collected supernatant was dried using a centrifugal concentrator and then dissolved in 100 ⁇ l of pyridine anhydrous 99.8% (Sigma-Aldrich) containing 0.2 mg/ml methyl palmitate.
- GC-MS gas chromatography-mass
- the area under the curve (AUC) of the peaks identified using MZMine was calculated, and a total of 106 types of metabolite profiles were obtained. These metabolite profiles were subjected to principal component analysis, and a heat map was created for the top 50% of metabolites that showed the greatest contribution to the second principal component. Furthermore, the similarity of the profiles of each metabolite in each experimental group was summarized in a dendrogram. The heat map and dendrogram are shown in Figure 2.
- the heatmap revealed that there were multiple metabolites in each group that showed similar metabolite level patterns. Based on the patterns of these metabolite levels, among the metabolites generally known to be associated with exercise, the metabolites that increased in the exercise load control group (swimming group) were classified as "activity", and the metabolites that decreased were classified as "rest”. In addition, among the metabolites generally known to be associated with nutritional status, the metabolites that increased in the exercise load control group (control group) were classified as "energy abundance”, and the metabolites that decreased were classified as "energy depletion”.
- metabolites classified as "energy abundance” or “energy depletion” related to nutritional state which increased in the no-exercise control group (Control group), decreased in the SL-administered groups (Swimming + 3'-SL group and swimming + 6'-SL group), and metabolites which decreased in the no-exercise control group (Control group) increased in the SL-administered groups.
- metabolites classified as "energy abundance” such as ascorbic acid, kynurenine, phenylalanine, and tyrosine, are known to affect exercise performance (Martin KS, Azzolini M, Ruas JL.
- the kynurenine connection how exercise shifts muscle tryptophan metabolism and affects energy homeostasis,the immune system, and the brain.
- the effects of phenylalanine on exercise-induced fat oxidation Apreliminary, double-blind, placebo-controlled, crossover trial.
- Example 3 The effect of administration of SL on the oxygen consumption rate (OCR) in mitochondria of C. elegans was evaluated.
- the L1 larvae were raised on NGM agar plates containing a solution of 3'-SL or 6'-SL dissolved in purified water at a concentration of 2 mg/ml and E. coli OP strain at 16°C for 72 hours until the L4 stage, and L4 larvae were obtained.
- the NGM agar plates were the same as in Example 1. 100 ⁇ L/plate of the solution containing 3'-SL or 6'-SL was used. Approximately 200 L1 larvae were raised/plate, and the amount of E. coli OP50 strain applied was approximately 10 7 cfu/plate.
- the control group was raised on an agar plate applied with purified water.
- the L4 larvae were suspended in M9-Tween buffer and collected. 30 ⁇ l of the suspension containing 80 L4 larvae was cultured in a sealed Polymethylmethacrylate (PMMA) 48-well plate (Merrem) at 22°C, and the OCR was measured after 1 hour.
- PMMA 48-well plate has two 20 mm thick plates, an upper plate and a lower plate.
- the upper plate is a 48-well plate filled with fluorinated silicone polymer as an oxygen-sensitive coating.
- the lower plate has 48 wells for culturing nematodes in M9 buffer, and the bottom of each well is coated with fluorinated silicone polymer.
- the OCR was measured using a Q2 Respiration Analyzer (Fytagoras B.V.).
- This Q2 Respiration Analyzer automatically tracks the oxygen concentration over a fixed period of time.
- a large number of capsuled samples can be placed inside the analyzer, and the oxygen concentration inside the capsule is automatically measured at fixed intervals and the data is output.
- the results of the oxygen consumption rate calculated from the oxygen concentration are shown in Figure 3. *** means p ⁇ 0.001.
- QQ255 strain (genotype: gsy-1 (gk397885) II., obtained from Caenorhabditis Genetics Center) (hereinafter also referred to as "QQ") in which the gsy-1 gene (NIH Gene ID: 174924) has been deleted
- CB7468 strain (genotype: acs-22 (gk373989) X., obtained from Caenorhabditis Genetics Center) (hereinafter also referred to as "CB") in which the acs-22 gene (NIH Gene ID: 181138) has been deleted
- CB CB7468 strain
- VC225 strain (genotype: tps-1 (ok373) X., obtained from Caenorhabditis Genetics Center) (hereinafter also referred to as "VC")
- WT wild-type Caenorhabditis elegans N2 strain
- the NB245 strain (genotype: aak-1(tm1944) III; aak-2(gt33) X., obtained from the Caenorhabditis Genetics Center) (hereinafter also referred to as "NB"), in which the aak-1 gene (NIH Gene ID: 176230) and the aak-2 gene (NIH Gene ID: 181727) have been deleted, the MT15434 strain (genotype: tph-1(mg280) II., obtained from the Caenorhabditis Genetics Center) (hereinafter also referred to as "MT"), the skn-1 gene (NIH Gene ID: The GR2245 strain (genotype: skn-1 (mg570) IV., obtained from: Caenorhabditis Genetics Center) (hereinafter also referred to as "GR") lacking the ador-1 gene (NIH Gene ID: 177343), the EG6890 strain (genotype: ador-1 (ox48
- Soares lab (hereinafter also referred to as "EG") lacking the ador-1 gene (NIH Gene ID: 174890), and the wild-type Caenorhabditis elegans N2 strain (hereinafter also referred to as "WT”) as a control were used, and the evaluation sample was applied to an NGM agar plate.
- the effect of adding 3'-SL or 6'-SL on endurance was evaluated in the same manner as in Example 1.
- the concentration of 3'-SL or 6'-SL in the evaluation samples was 2 mg/ml. Purified water was used as a control.
- the results are shown in Figure 5.
- (-) indicates no exercise load, and (+) indicates exercise load.
- * indicates p ⁇ 0.05, ** indicates p ⁇ 0.01, and *** indicates p ⁇ 0.001.
- the agent of the present invention contains sialyllactose or a salt thereof as an active ingredient, and thereby exerts at least one of the effects of improving endurance and reducing physical fatigue.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne : un agent pour améliorer l'endurance et/ou réduire la fatigue physique qui contient du sialyllactose ou un sel de celui-ci en tant que principe actif ; l'utilisation de sialyllactose ou d'un sel de celui-ci pour produire l'agent ; le sialyllactose ou un sel de celui-ci à utiliser en tant qu'agent ; un procédé pour améliorer l'endurance et/ou réduire la fatigue physique ; une composition qui est au moins l'un parmi un activateur de protéine kinase de monophosphate d'adénosine et des compositions pour prévenir la sarcopénie, pour améliorer le métabolisme lipidique, pour améliorer la résistance à l'insuline, et pour améliorer le métabolisme du glucose ; un activateur de glycogène synthase ; et une composition pour améliorer l'endurance.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022-199671 | 2022-12-14 | ||
JP2022199671 | 2022-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024128298A1 true WO2024128298A1 (fr) | 2024-06-20 |
Family
ID=91485959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2023/044944 WO2024128298A1 (fr) | 2022-12-14 | 2023-12-14 | Agent pour améliorer l'endurance et/ou réduire la fatigue physique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024128298A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010131712A1 (fr) * | 2009-05-15 | 2010-11-18 | 財団法人ヒューマンサイエンス振興財団 | Agent pharmaceutique destine au traitement des maladies associees a une diminution de la fonction de la proteine gne, composition et additif alimentaires |
WO2019087140A1 (fr) * | 2017-11-02 | 2019-05-09 | Glycom A/S | Un ou plusieurs hmos pour réduire ou prévenir la fatigue et/ou améliorer la focalisation ou la concentration |
JP2021127321A (ja) * | 2020-02-14 | 2021-09-02 | 森永乳業株式会社 | 持久力向上用組成物 |
-
2023
- 2023-12-14 WO PCT/JP2023/044944 patent/WO2024128298A1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010131712A1 (fr) * | 2009-05-15 | 2010-11-18 | 財団法人ヒューマンサイエンス振興財団 | Agent pharmaceutique destine au traitement des maladies associees a une diminution de la fonction de la proteine gne, composition et additif alimentaires |
WO2019087140A1 (fr) * | 2017-11-02 | 2019-05-09 | Glycom A/S | Un ou plusieurs hmos pour réduire ou prévenir la fatigue et/ou améliorer la focalisation ou la concentration |
JP2021127321A (ja) * | 2020-02-14 | 2021-09-02 | 森永乳業株式会社 | 持久力向上用組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9446006B2 (en) | Hydroxytyrosol combinations for enhancing mitochondrial function and energy production | |
JP6255079B2 (ja) | シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤 | |
JP6920071B2 (ja) | アディポネクチン分泌向上剤 | |
KR101692033B1 (ko) | D-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물 | |
US20110319497A1 (en) | Ampk activator | |
US20120010285A1 (en) | Agent for promoting energy consumption | |
US20120309716A1 (en) | Motor Function Improver | |
JP5240810B2 (ja) | D−プシコースの血中d−フラクトース濃度上昇抑制への使用 | |
US20230117757A1 (en) | Coenzyme q production accelerator and method for accelerating coenzyme q production | |
JP5281268B2 (ja) | 筋力向上剤 | |
TWI225789B (en) | Compositions inhibiting muscle atrophy | |
TW202135801A (zh) | 含有芝麻素類及吡咯喹啉醌(pqq)之組成物 | |
EP2617429B1 (fr) | Agent d'amélioration de l'oxydation des graisses et du métabolisme énergétique | |
WO2024128298A1 (fr) | Agent pour améliorer l'endurance et/ou réduire la fatigue physique | |
KR101206543B1 (ko) | 율피 추출물을 포함하는 지방간의 예방 또는 치료용 조성물 | |
JP2009261335A (ja) | 食品組成物 | |
JP2008545766A (ja) | (−)−エピガロカテキンガレートの新規使用 | |
JP2008074734A (ja) | インスリン抵抗性改善剤 | |
KR20170027272A (ko) | D-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물 | |
CN103108556A (zh) | 绒毛戴星草衍生成分 | |
US20160184248A1 (en) | Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response | |
CN115867289A (zh) | 含有nr及/或nmn与芝麻素类的组合物 | |
JP5723276B2 (ja) | コレステロールエステル転送タンパク質阻害剤 | |
KR101697260B1 (ko) | 보글리보즈를 유효성분으로 함유하는 비만 개선, 정장 또는 장내 균총 개선용 조성물 | |
US20170209511A1 (en) | Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients |